Christine is one of the first patients in Norway to receive Airsonett TLA treatment (Temperature-controlled Laminar Airflow) for her allergic disease. She has had asthma and allergies since preschool. With TLA treatment, she has gotten a new life. She is less ill and has a much better quality of life.
Airsonett announced today a new observational study showing a significant effect of Airsonett TLA (Temperature-controlled Laminar Airflow) for treating adult atopic dermatitis (AD) patients. The proof-of-concept study is published in the Journal of the European Academy of Dermatology and Venereology.
The information on this website is intended for residents of the United States only. The product described here is FDA 510(k) cleared for use in the United States. Product indications and availability may differ in other regions.